Physician

John Charles Long, MD

According to 2025 Medicare claims, John Long, MD (NPI: 1356351043) practices dermatology in the Deltona-Daytona Beach-Ormond Beach, FL market, with the plurality of this provider's patient population coming from Volusia, FL. This provider's primary affiliated billing organization is LONG DERMATOLOGY PA (NPI: 1801003496; TIN: 593513032) and primary practice location at 32174-5138.

Long's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,375 traditional Medicare patients, billed 26,380 HCPCS/CPT codes, and received $1,002,352 in Medicare payments. The top billing code was 17281 (Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm). Part D data shows 1,345 prescription claims across 470 beneficiaries totaling $302,211 in drug costs, led by Otezla (Apremilast). Open Payments data shows 2 records totaling $56. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $98,131 to $302,211. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,594	29,133	$862,730
2016	1,668	31,858	$902,715
2017	1,602	32,876	$910,461
2018	1,582	32,706	$930,978
2019	1,586	31,997	$1,016,937
2020	1,448	29,773	$919,304
2021	1,469	29,436	$1,062,147
2022	1,439	28,321	$1,033,810
2023	1,447	28,356	$982,981
2024	1,375	26,380	$1,002,352

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	360	935	$98,131
2016	383	1,117	$147,993
2017	422	1,244	$156,329
2018	415	1,164	$138,267
2019	417	1,203	$172,060
2020	423	1,173	$191,373
2021	416	1,248	$205,579
2022	464	1,331	$263,275
2023	438	1,235	$290,828
2024	470	1,345	$302,211

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
17281	Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm	279	364	$136
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	865	1,698	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	817	2,557	$65
17000	Destruction of precancer skin growth, 1 growth	1,136	2,358	$36
17003	Destruction of precancer skin growth, 2-14 growths	1,089	13,788	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Otezla	Apremilast	13	390	$73,970
Vtama	Tapinarof	11	315	$15,055
Clobetasol Propionate	Clobetasol Propionate	85	2,670	$4,919
Fluocinonide	Fluocinonide	124	3,246	$4,301
Triamcinolone Acetonide	Triamcinolone Acetonide	312	8,489	$3,061

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$56	Regeneron Healthcare Solutions, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for John Charles Long, MD?

Tedicare shows public-source Medicare data for John Charles Long, MD (NPI 1356351043), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does John Charles Long, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to John Charles Long, MD?

John Charles Long, MD is linked to LONG DERMATOLOGY PA (billing NPI 1801003496) in the available physician profile data.

Does John Charles Long, MD have Open Payments data?

John Charles Long, MD has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.